Abstract In the theater of modern oncology, macroscopic victory is an illusion. Traditional imaging and standard biopsies celebrate empty battlefields, but Minimal Residual Disease (MRD) and molecular remnants remain hidden from sight. Enter advanced staging paradigms and automated biomarker discovery platforms. By quantifying exact tumor dimensions under rigorous RECIST criteria and mapping trace multi-pathway signatures, clinicians transcend subjective diagnostics. This…